QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The drug is indicated for mild and transient episodes of heart block
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
The government has recently enhanced the incentive granted to storeowners from existing Rs. 2.50 lakh to Rs. 5.00 lakh given at the rate of 15% of monthly purchases made, subject to a ceiling of Rs. 15,000 per month
The company posted net profit of Rs.34.24 crores for the period ended June 30, 2020.
The goal for the project is the identification and optimization of anti-viral compounds.
Subscribe To Our Newsletter & Stay Updated
